@entity10569 in a dosage of 200 mg 3 times daily was given to 24 @entity1 with type II A (n = 8), II B (n = 1) and IV (n = 15) hyperlipoproteinaemia for 4.5 years. In type II A the content of total @entity165 and that of low density lipoprotein in serum decreased by 10-23 and 11-34 percent over the years compared to pretreatment. In type IV the content of total @entity1674 and that of very low density lipoprotein decreased by 28-39 and 38-52 percent, respectively, over the years. High density lipoprotein @entity165 increased in both types. The "atherogenic index" was reduced by the drug. The effect remained through the 4.5 years of treatment. Compliance to the drug was good. Changes in safety laboratory parameters were minor and reversible. No subjective side-effects occurred and no cases of @entity1085 or @entity5 were noted. It is concluded that @entity10569 is a safe, convenient and effective serum lipid-lowering drug suitable for the use in primary and secondary prevention of @entity731 .

Effect of XXXX during 4.5 years of treatment of hyperlipoproteinaemia.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1085 :: ('MESH:D005705', 'Disease') :: ['gallbladder disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity10569 :: ('MESH:D001629', 'Chemical') :: ['bezafibrate', 'Bezafibrate'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic disease'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity10569 :: (MESH:D001629,Chemical) :: ['bezafibrate']
